Accolade (NASDAQ:ACCD) Trading 2.9% Higher

Accolade, Inc. (NASDAQ:ACCD) traded up 2.9% during trading on Wednesday . The stock traded as high as $8.67 and last traded at $8.64. 259,204 shares were traded during trading, a decline of 64% from the average session volume of 712,323 shares. The stock had previously closed at $8.40.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Stifel Nicolaus reduced their price target on shares of Accolade from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, January 4th. Wells Fargo & Company increased their target price on shares of Accolade from $10.00 to $12.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 9th. Raymond James increased their target price on shares of Accolade from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Tuesday, January 9th. Barclays began coverage on shares of Accolade in a report on Wednesday, January 3rd. They issued an “equal weight” rating and a $13.00 target price for the company. Finally, SVB Leerink began coverage on shares of Accolade in a report on Monday, February 26th. They issued an “outperform” rating and a $16.00 target price for the company. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $15.67.

Accolade Stock Down 0.4 %

The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.48. The business has a 50-day moving average price of $10.15 and a 200 day moving average price of $9.92.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ACCD. BluePath Capital Management LLC bought a new position in shares of Accolade during the 3rd quarter valued at approximately $28,000. DekaBank Deutsche Girozentrale bought a new position in shares of Accolade during the 3rd quarter valued at approximately $28,000. AJOVista LLC bought a new position in shares of Accolade during the 4th quarter valued at approximately $68,000. State of Wyoming boosted its position in shares of Accolade by 46.6% during the 2nd quarter. State of Wyoming now owns 5,247 shares of the company’s stock valued at $71,000 after acquiring an additional 1,669 shares during the last quarter. Finally, First Republic Investment Management Inc. bought a new position in shares of Accolade during the 2nd quarter valued at approximately $75,000. 84.99% of the stock is currently owned by institutional investors.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.